TrialDiabetes, obesity & metabolism2018

Insulin secretion predicts the response to therapy with exenatide plus pioglitazone, but not to basal/bolus insulin in poorly controlled T2DM patients: Results from the Qatar study.

Muhammad Abdul-Ghani et al.PubMed ↗Publisher ↗

No numbers read from the abstract.